Summary
42 / 100 · Bulios Score
What speaks for it
- Revenue grew by 29% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 82% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- It missed profit estimates 5 times in the last 8 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 48% a year over 5 years. Over the last 3 years it grew by 29% a year. For the next fiscal year analysts expect revenue to grow by 82%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $109.4M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 5
- Sell 3
Today's price within the analysts' price targets
The average target of $13.75 is 77% above today's price. 53% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- UNITED STATES 79%
- Non-US 21%
UNITED STATES brings in 79% of revenue.
Segments in detail